Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients: Two Centers' Experiences

Luis Espinosa-Aguilar, Jaime S. Green, Graeme N. Forrest, Edward D. Ball, Richard Maziarz, Lynne Strasfeld, Randy Allison Taplitz

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use (≥20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality.

Original languageEnglish (US)
Pages (from-to)566-573
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Hematopoietic Stem Cell Transplantation
Respiratory Tract Infections
Human Influenza
Pandemics
Mortality
H1N1 Subtype Influenza A Virus
Incidence
Virus Diseases
Prednisone
Infection
Cough
Antiviral Agents
Fever
Steroids
Confidence Intervals
Morbidity

Keywords

  • 2009 Influenza virus
  • Immunocompromised
  • Lower respiratory tract infection

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients : Two Centers' Experiences. / Espinosa-Aguilar, Luis; Green, Jaime S.; Forrest, Graeme N.; Ball, Edward D.; Maziarz, Richard; Strasfeld, Lynne; Taplitz, Randy Allison.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 4, 04.2011, p. 566-573.

Research output: Contribution to journalArticle

Espinosa-Aguilar, Luis ; Green, Jaime S. ; Forrest, Graeme N. ; Ball, Edward D. ; Maziarz, Richard ; Strasfeld, Lynne ; Taplitz, Randy Allison. / Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients : Two Centers' Experiences. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 4. pp. 566-573.
@article{65835eadda104f76bfa4ba31584ff76d,
title = "Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients: Two Centers' Experiences",
abstract = "Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52{\%} (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95{\%} confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22{\%} (6/27), and that in patients with LRTI was 43{\%} (6/14). Chronic steroid use (≥20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality.",
keywords = "2009 Influenza virus, Immunocompromised, Lower respiratory tract infection",
author = "Luis Espinosa-Aguilar and Green, {Jaime S.} and Forrest, {Graeme N.} and Ball, {Edward D.} and Richard Maziarz and Lynne Strasfeld and Taplitz, {Randy Allison}",
year = "2011",
month = "4",
doi = "10.1016/j.bbmt.2010.07.018",
language = "English (US)",
volume = "17",
pages = "566--573",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Novel H1N1 Influenza in Hematopoietic Stem Cell Transplantation Recipients

T2 - Two Centers' Experiences

AU - Espinosa-Aguilar, Luis

AU - Green, Jaime S.

AU - Forrest, Graeme N.

AU - Ball, Edward D.

AU - Maziarz, Richard

AU - Strasfeld, Lynne

AU - Taplitz, Randy Allison

PY - 2011/4

Y1 - 2011/4

N2 - Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use (≥20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality.

AB - Respiratory virus infections, such as influenza A, cause significant morbidity in hematopoietic stem cell transplantation (HSCT) recipients. The clinical characteristics and impact of infection with the novel H1N1 virus in this patient population is not yet well defined, however. HSCT recipients diagnosed with proven or probable H1N1 during the 2009 pandemic were identified and charts were retrospectively reviewed with analysis of clinical descriptions, risk factors, diagnosis, treatments, and outcomes. Twenty-seven patients from two medical centers were identified. Fever and cough were the most common presenting symptoms. The incidence of influenza lower respiratory tract infection (LRTI) was 52% (14/27). Compared with patients with LRTI, those with influenza upper respiratory tract infection (URTI) were more likely to have a classic influenza-like syndrome. Compared to patients with URTI, those with LRTI were started on antiviral therapy significantly later after symptom onset (3.0 days vs 6.58 days after onset of symptoms; P = .03; 95% confidence interval [CI], 0.29-6.8). Overall influenza-related 30-day mortality was 22% (6/27), and that in patients with LRTI was 43% (6/14). Chronic steroid use (≥20 mg/day of prednisone equivalent) at the time of presentation was associated with LRTI (P = .006) and mortality (P = .003) on univariate analysis. Five cases were hospital-acquired. In this first season of the novel H1N1 pandemic, infection in HSCT often presented as an atypical severe illness with a high incidence of LRTI and high mortality.

KW - 2009 Influenza virus

KW - Immunocompromised

KW - Lower respiratory tract infection

UR - http://www.scopus.com/inward/record.url?scp=79952621487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952621487&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2010.07.018

DO - 10.1016/j.bbmt.2010.07.018

M3 - Article

C2 - 20708084

AN - SCOPUS:79952621487

VL - 17

SP - 566

EP - 573

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 4

ER -